A Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Prothione™ Capsules for Mild to Moderate Coronavirus Disease 2019 (COVID-19)

Principal investigator: Mutabazi Vincent
Check PI profile

Investigators

Vincent Mutabazi, Malayika Rosine, Clarisse Musanabaganwa, Pacifique Ndishimye, Anthony BAZATSINDA, Sumanyi Jean Claude, Lambert Mwambarangwe, Marie Michèle UMULISA, Rosette Busasa

Study information

  • Research Area: Covid-19
  • Research type: Clinical Trial
  • Start date: Jan 01, 2021
  • End date: Dec 31, 2021

Study aim of the objectives

The purpose of this study is to assess the efficacy and safety of Prothione™ capsules administered orally
twice a day for 30 days in subjects with mild to moderate COVID-19.

Study setting/Area (Location)

COVID-19 Treatment Centres

Implementing institution

Rinda Ubuzima, RBC

Department/Division

RIDS

Impact on Policy

To inform guideline on treatment of COVID-19 patients

Related research

Login
Support